Aida has recently had excellent results validating it’s approach to ensuring that every cancer patient gets the best drugs to treat their tumour. Their proprietary algorithms analyse the expression pattern of more than 300 genes in tumour biopsies. This allows them to provide doctors with advice on which drugs are likely to (and not to) have a beneficial effect.

Recent work on data from the US I-Spy2 trial is the latest evidence of the value of the approach and was accepted as a ‘late-breaking abstract’ at the San Antonio Breast Cancer Symposium.

More details on the Aida website.

Next >